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induced by a potentially toxic substance 
such as LPS, and even in the setting of 
heightened renal infl ammation, under-
scores the appeal of preconditioning and 
the recruitment of cytoprotective path-
ways as strategies to prevent AKI.
REFERENCES
1. Zager RA, Johnson ACM, Lund S. ‘Endotoxin 
tolerance’: TNF-α hyper-reactivity and tubular 
cytoresistance in a renal cholesterol loading state. 
Kidney Int 2007; 71: 496–503. 
2. Honda N, Hishida A, Ikuma K et al. Acquired 
resistance to acute renal failure. Kidney Int 1987; 
31: 1233–1238.
3. Bonventre JV. Kidney ischemic preconditioning. 
Curr Opin Nephrol Hypertens 2002; 11: 43–48.
4. Zager RA, Baltes LA, Sharma HM et al. Responses 
of the ischemic acute renal failure kidney to 
additional ischemic events. Kidney Int 1984; 26: 
689–700.
5. Heemann U, Szabo A, Hamar P et al. 
Lipopolysaccharide pretreatment protects from 
renal ischemia/reperfusion injury: possible 
connection to an interleukin-6-dependent 
pathway. Am J Pathol 2000; 156: 287–293.
6. Zager RA, Burkhart KM, Johnson AC et al. 
Increased proximal tubular cholesterol content: 
implications for cell injury and “acquired 
cytoresistance”. Kidney Int 1999; 56: 1788–1797.
7. Deng J, Kohda Y, Chiao H et al. Interleukin-10 
inhibits ischemic and cisplatin-induced acute 
renal injury. Kidney Int 2001; 60: 2118–2128.
8. Park KM, Byun JY, Kramers C et al. Inducible 
nitric-oxide synthase is an important contributor 
to prolonged protective effects of ischemic 
preconditioning in the mouse kidney. J Biol Chem 
2003; 278: 27256–27266.
9. Noiri E, Peresleni T, Miller F et al. In vivo 
targeting of inducible NO synthase with 
oligodeoxynucleotides protects rat kidney 
against ischemia. J Clin Invest 1996; 97: 2377–
2383.
10. Gladwell M. The Tipping Point: How Little Things 
Can Make a Big Difference. Little, Brown and Co.: 
Boston, 2002, pp 301.
see original article on page 504
Renal albumin handling: A look at 
the dark side of the filter
M Gekle1
Renal albumin handling is of major interest because albuminuria 
is an important risk factor for reno-cardiovascular diseases. In this 
issue a challenging study attempts to shift the paradigm of very low 
fractional albumin filtration and degradation in proximal tubule 
cells. The conclusions are of great potential relevance but require 
urgent validation so that we gain a clearer view of the dark side of the 
glomerular filter. 
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Renal protein handling, especially renal 
albumin handling, attracts increasing 
interest in basic renal research and gains 
growing importance in clinical nephrol-
ogy as well as cardiovascular medicine. 
First we have the basic desire to under-
stand the kidneys’ function as well as 
possible mechanisms leading to dysfunc-
tion, such as proteinuria. Furthermore, 
the excretion of albumin with the fi nal 
urine (albuminuria) is being recognized 
as a major risk factor for renal and car-
diovascular diseases. Although there is a 
clear epidemiological correlation, there 
is no rational explanation of the causa-
tive links.1,2 Recently, pressure-induced 
and mineralocorticoid receptor-medi-
ated damage of podocytes has been sug-
gested as a link between albuminuria and 
risk of cardiovascular diseases.3 Finally, 
the protein load in the proximal tubular 
lumen has been recognized as an impor-
tant parameter for the development of 
tubulointerstitial diseases and ultimately 
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for the progression of renal-function 
decline.1,4 Albuminuria, therefore, is 
marker and motor of renal and cardio-
vascular diseases.
As for every plasma constituent enter-
ing the kidneys, the basic equation 
arterial input = venous output + urine 
output + metabolism
holds true for serum albumin. How-
ever, this equation treats the kidney as a 
black box and neglects the crucial intrare-
nal mechanisms leading to urine forma-
tion and metabolism. Urine output results 
from fi ltration + secretion – reabsorption. 
Th us the complete equation is
arterial input = venous output + (fi ltra-
tion + secretion – reabsorption) + metab-
olism.
In order to understand the fate of any 
substance in the kidney we have to know 
its behavior with respect to filtration, 
secretion, and reabsorption. For serum 
albumin there is consensus that no rel-
evant secretion occurs. Th us, we have to 
understand fi ltration and reabsorption 
of albumin.
Th e composition of glomerular ultrafi l-
trate depends on the permeability proper-
ties of the glomerular fi lter barrier, which 
is negatively charged and has pores with 
a theoretical mean diameter of about 
4 nm.1 Th us, under physiological condi-
tions molecules with eff ective diameters 
greater than 4 nm are not freely fi ltered 
but are retained to an increasing extent 
as the diameter increases, that is, as the 
fractional fi ltration (= substrate concen-
tration in renal ultrafi ltrate / substrate 
concentration in plasma) decreases from 
1 to 0. Furthermore, negatively charged 
macromolecules with eff ective diameters 
close to the fi lter pore diameter seem to be 
restricted to a greater extent as compared 
with neutral molecules of comparable 
size. For a freely fi ltered substance, such 
as glucose, the fi ltered amount can be eas-
ily determined as the product of glomeru-
lar fi ltration rate × plasma concentration. 
For albumin the eff ective radius is in the 
range of 7.5 nm,5 resulting in a fractional 
fi ltration <<1, (Figure 1) which has been 
previously assumed to range between 
0.0005 and 0.0007.1,6 Further calculations 
suggested that fractional fi ltration may be 
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even lower. When these values were used 
together with a plasma albumin concen-
tration of about 45 g per liter, the albu-
min concentration in renal ultrafi ltrate 
of humans was estimated in the range of 
20–30 mg per liter. Th ese values were in 
good agreement with albumin concen-
trations determined by micropuncture 
studies.6 In 1999, a study by the group of 
Eppel and Comper,7 using a more indirect 
technique in order to determine the albu-
min concentration in renal ultrafi ltrate, 
came to the conclusion that the concen-
trations are much higher and initiated a 
controversial debate.
Th e group of Russo and Comper8 (this 
issue) now present new and challenging 
data regarding renal albumin handling. 
In this study, a new and elegant tech-
nique was applied: intravital two-photon 
microscopy. Th e purpose of the applica-
tion of this new technique was the cir-
cumvention of the apparent limitations 
associated with former methods. When 
free-fl ow micropuncture studies are used 
to determine the concentration of a sub-
stance in the tubular lumen that is present 
at much higher concentrations in plasma, 
it is always of major importance to pre-
vent plasma or interstitial fl uid contami-
nation in the collecting pipette in order to 
avoid an overestimation of fi ltration. Th e 
indirect method applied by Eppel et al.7 
relied on various assumptions and calcu-
lations that could have easily resulted in 
an overestimation.
The method used by Russo et al.8 
— intravital two-photon microscopy 
— allows, in principle, the simultaneous 
measurement of the fl uorescence signal 
of a labeled substance in the glomerular 
capillaries and the Bowman space (i.e., the 
initial part of the proximal tubule), and 
comparison of the two in a paired setting. 
Furthermore, tissue remains intact. Th is 
approach appears ideal for measurement 
of fractional fi ltration and has been suc-
cessfully applied for the determination of 
the glomerular sieving coeffi  cient (GSC) 
of fl uorescein derivatives, for example. 
Fluorescein derivatives are fi ltered freely 
and therefore yield a signal in the Bow-
man space that is high enough for direct 
comparison with the signal from the cap-
illaries and is substantially above back-
ground. For fl uorescently labeled albumin 
the situation is more complicated, because 
tubular concentrations are much lower 
than those in the capillaries. When the 
fl uorescence of plasma albumin was kept 
in the working range (1–220 intensity 
levels) of the imaging system, the tubular 
signal was very close to background noise. 
Increasing the amount of labeled plasma 
albumin to achieve a better tubular signal-
to-noise ratio shift s the capillary signal out 
of the working range and requires in vitro 
assessment. Th us, although intravital two-
photon microscopy is theoretically ideally 
suited to determine GSC, in the case of 
albumin the actual setup used worked at 
its edge, and some of the gray levels used 
for GSC calculations seem to be very close 
to background noise. Albeit a visual tech-
nique is used, the authors admit that the 
tubular signal of importance oft en cannot 
be seen but can only be detected by the 
camera. In addition, the signal range of 
the system (1–220) can never yield a GSC 
smaller than 1:220 (or even greater aft er 
background subtraction). Th us, when a 
signal is obtained, GSC is always greater 
than this value.
Th e fractional fi ltration (or GSC) of 
albumin derived in the actual study8 is 
approximately 0.04 and therefore 50 
times higher than the values accepted 
until now (which the system, for technical 
reasons, would not be able to reproduce) 
(Figure 1). Th is presents a real shift  in the 
paradigm of renal albumin handling and 
therefore is certainly an important con-
tribution to the fi eld. However, at present, 
the conclusions drawn have to be viewed 
under consideration of the above-men-
tioned limitations. It is now of eminent 
importance that these fi ndings be repro-
duced as such and furthermore that their 
validity also be tested in other systems, 
especially in humans. If these prerequi-
sites are fulfi lled, a true shift  in paradigm 
will have happened and will have signifi -
cantly broadened our understanding of 
renal physiology and possibly also some 
concepts of pathophysiology.
According to this new view, the amount 
of fi ltered albumin is 50 times higher than 
assumed before, and daily fi ltration would 
exceed the amount of total plasma albu-
min.1 According to the basic equation 
of renal substance handling mentioned 
above, this means that 50 times more 
albumin must be reabsorbed, a process 
taking place in the proximal tubule.9 In 
recent years it has been demonstrated 
nicely that albumin reabsorption results 
from receptor-mediated endocytosis 
(Figure 1), the receptor being cubilin 
(high affi  nity) and megalin (low affi  n-
ity). Within proximal tubular cells the 
albumin taken up is delivered to lyso-
somes and the degradation products are 
GSC < 0.001
Apical uptake by
receptor-mediated
endocytosis Delivery of
degradation
products
Excreted amount << Filtered amount
GSC ~ 0.04
Apical uptake by
receptor-mediated
endocytosis
Intact delivery
by transcytosis
Excreted amount << Filtered amount
Current model Proposed model
Figure 1| Comparison of the current model of renal albumin handling, as described in most 
of the publication, with the new model proposed by Russo et al. GSC, glomerular sieving 
coefficient.
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fi nally delivered across the basolateral 
membrane into the peritubular blood. 
However, this process has only a limited 
capacity. Th e ability of proximal tubular 
cells to degrade protein would most prob-
ably not be able to cope with a 50-fold 
increased load. However, it is unlikely 
that this load would reach the lysosomes, 
because the uptake machinery is satu-
rated previously. So how is the 50-fold 
increased load of albumin reabsorbed? 
Russo et al.8 suggest that the major part 
of reabsorption takes place by transcytosis 
of intact albumin (Figure 1), by contrast 
to the conclusions drawn to date in the 
large majority of studies.9 Th is concept 
would present the second shift  of para-
digm. However, this issue is supported by 
only a single fi gure of an apparently non-
systematic preliminary immunoelectron 
microscopic study. Th e suggested value 
of the GSC of albumin implies that the 
vast majority of the fi ltered albumin must 
be transcytosed intact. It is therefore sur-
prising that this transcytotic pathway was 
not detectable in previous studies. Th ere 
may be some transcytosis, but at the 
moment the evidence for a large rate of 
transcytotic reabsorption is rather weak. 
Transcytosis may explain how the limited 
degradation capacity is bypassed, but it 
does not explain how an eff ective uptake 
across the apical membrane occurs, in 
view of the saturated known receptors for 
albumin. Fluid-phase transcytosis is most 
probably not suffi  cient. Again, it is now 
of eminent importance to validate these 
data and verify or falsify the concept of 
substantial transcytosis.
We are confronted with a study apply-
ing a new and elegant technique to an 
old but very important issue, which up 
to now was never resolved unequivocally. 
Th e conclusions drawn attempt to shift  
two paradigms and are therefore of great 
potential relevance but require urgent 
validation. If these data can be verifi ed 
by others and also in other systems, we 
might gain a clearer view of the dark side 
of the fi lter.
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Measuring risk in end-stage 
renal disease: Is N-terminal pro 
brain natriuretic peptide a useful 
marker?
MH Rosner1
Natriuretic peptides are important in the maintenance of body volume 
homeostasis. There has been interest in utilizing the levels of these 
peptides to diagnose and prognosticate cardiovascular disease. In  end-
stage renal disease, the diagnostic utility of these peptides is limited. 
Madsen et al. report that levels of N-terminal pro brain natriuretic 
peptide (NT-proBNP) levels  offer important information on the risk of 
mortality in patients undergoing hemodialysis.
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Cardiovascular disease is the leading cause 
of mortality in patients with end-stage 
renal disease (ESRD). Although tradi-
tional risk factors such as elevated low-
density lipoprotein levels, hypertension, 
diabetes mellitus, and smoking account 
for a substantial percentage of the risk 
factor profi le in the general population, in 
patients with ESRD these traditional risk 
factors are limited in their ability to predict 
future events.1 Th us, attention has turned 
to the identifi cation of novel risk factors 
that can both refi ne prognosis and serve 
as potential targets of intervention. Th us, 
markers such as C-reactive protein, serum 
albumin, asymmetric dimethyl arginine, 
and numerous others have been shown to 
be independent predictors of death risk in 
the dialysis population.1 Th ose nontradi-
tional risk factors that can be shown to be 
causal are especially important, as they can 
signal both the presence and the severity 
of disease as well as serving as both guides 
and targets for therapy. In this context, 
the serum levels of natriuretic peptides 
in ESRD patients would seem an ideal 
candidate for such a causal risk factor for 
cardiovascular events.
Natriuretic peptides are a well-described 
family of hormones with a major role in 
sodium and body volume homeostasis.2 
Th e major members of this group of hor-
mones are atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP), along 
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